Boston Scientific (BSX) Q2 2026: Watchman Drops to -7% in H2, Pivots Growth Mix for 2027
Boston Scientific reset its growth trajectory as two former engines—Watchman and Electrophysiology—face abrupt slowdowns, driving a guidance cut and a strategic pivot to cost efficiency and pipeline launches. The company’s diversified portfolio, with 75% of revenue still growing at a resilient 6%, now shoulders the outlook, while management signals margin discipline and a multi-year plan to re-accelerate in 2028. Investors are now watching execution on restructuring, pipeline launches, and the stabilization of challenged segments for signs of upside or further risk.
Summary
- Growth Reliance Shifts: Core portfolio now anchors outlook as Watchman and EP decelerate sharply.
- Margin Discipline Intensifies: $500 million restructuring targets cost savings and future margin expansion.
- 2028 Pipeline Bets: Multiple high-impact launches and M&A are positioned to restore double-digit growth.
Business Overview
Boston Scientific is a global medical technology company specializing in minimally invasive devices and therapies for interventional cardiology, electrophysiology (EP), neuromodulation, endoscopy, urology, and vascular interventions. It generates revenue by selling devices and solutions to hospitals and clinics, with major segments including Interventional Cardiology, Electrophysiology, Watchman (left atrial appendage closure), Neuromodulation, Endoscopy, and Urology. The company’s business model relies on continuous product innovation, clinical adoption, and expansion into new therapeutic areas, with a growing presence in high-growth adjacencies through both organic R&D and tuck-in acquisitions.
Performance Analysis
Boston Scientific delivered 7% organic revenue growth in Q2, at the top end of guidance, but the underlying growth mix is shifting rapidly. The core portfolio—comprising about 75% of total revenue—maintained a 6% growth pace, led by Interventional Cardiology, Neuromodulation, and Endoscopy. However, two former hyper-growth engines—Watchman and Electrophysiology—showed marked deceleration, with Watchman’s U.S. standalone procedures falling by low teens and global growth expected to decline mid to high single digits in H2.
Margin performance was mixed. Adjusted operating margin expanded by 70 basis points to 28.4%, aided by tax favorability and disciplined spending, but management acknowledged product mix pressure and the early impacts of restructuring. The company also absorbed a $75 million product liability charge and recognized $80 million in tariff refunds, which are not expected to recur. Share repurchases reduced the share count more than anticipated, modestly boosting EPS, but the headline is a guidance cut: full-year organic revenue growth is now pegged at 5% to 6%, with EPS growth of 7% to 8%—both below recent multi-year trends.
- Watchman Downturn: Global Watchman revenue is projected to decline mid to high single digits in H2, with management not assuming improvement in 2027.
- Electrophysiology Share Loss: U.S. EP growth has slowed to low single digits as PFA adoption accelerates and competitive share shifts intensify.
- Core Portfolio Resilience: Interventional Cardiology, Neuromodulation, and Endoscopy delivered double-digit growth, offsetting challenged segments.
Overall, the business is in a transition phase, with near-term headwinds in two key growth drivers, but continued strength in diversified segments and a disciplined approach to cost and capital allocation.
Executive Commentary
"Our guidance reduction is concentrated in two areas. First, Watchman, where the US market has slowed sharply and unexpectedly, primarily driven by compounding clinical evidence which has impacted referral patterns. In second EP, where we did not anticipate the degree of competitive share movement, we're now seeing in the US market. While we are sharpening our forecasting processes and taking action to address controllable headwinds, our underlying assumptions are that these dynamics continue in 27, resulting in revenue growth below our WAMGR and limited adjusted EPS growth."
Mike Mahoney, Chairman and Chief Executive Officer
"We anticipate this comprehensive company-wide program will deliver run rate savings of approximately $500 million exiting 2029 in the areas of supply chain optimization, targeted functional transformation, org structure evolution, as well as focused reductions in indirect spending to drive sustained cost efficiencies. We expect to realize over half of our run rate savings and incur over half of our program spend exiting 2027. This will position the company to return to meaningful operating margin expansion and strong adjusted EPS growth in 2028 and beyond."
John Monson, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Portfolio Mix Shift and Growth Anchors
With Watchman and EP losing momentum, Boston Scientific’s growth is now anchored by Interventional Cardiology, Neuromodulation, and Endoscopy, which together represent 75% of revenue and are expected to sustain 6% growth. Management is prioritizing these segments for investment and pipeline acceleration, aiming to buffer volatility from challenged businesses.
2. Cost Structure Overhaul
A $500 million restructuring program targets supply chain, functional, and organizational efficiency, with the goal of restoring margin expansion and funding future growth bets. Over half of the savings and costs are expected by 2027, with initial benefits in SG&A and longer-term impact in COGS.
3. Pipeline and Adjacency Expansion
Boston Scientific is doubling down on pipeline launches and M&A to drive the next growth cycle. Key launches in 2027–2028 include IVL (intravascular lithotripsy), hypertension therapies, the Penumbra acquisition, TAVR (transcatheter aortic valve replacement) via Mirus, and novel EP platforms (Ultra, ICE, Fairflex). Management estimates these seven launches address a $25 billion total addressable market (TAM).
4. Watchman and EP: Containment and Recovery Tactics
For Watchman, management is executing a three-pronged plan: physician education, commercial investment, and direct-to-patient activation to rebuild referrals and stabilize market share. In EP, the focus is on new product launches (Ultra, ICE, Fairflex) to regain lost share and restore growth by late 2027 and 2028.
5. Capital Allocation and M&A Discipline
Capital deployment remains focused on high-impact tuck-in M&A (e.g., Penumbra, Mirus), opportunistic share buybacks, and funding pipeline launches. Management is clear that future margin and EPS expansion depend on disciplined reinvestment and cost controls.
Key Considerations
This quarter marks a strategic inflection as Boston Scientific transitions from a dual-engine growth model to a broader, more diversified platform, while absorbing near-term headwinds in two high-profile businesses.
Key Considerations:
- Growth Engine Reset: The company’s ability to pivot from Watchman/EP-driven growth to a multi-segment approach will determine medium-term stability.
- Restructuring Execution: Realizing $500 million in cost savings is critical for restoring margin expansion, especially as product mix headwinds persist.
- Pipeline Delivery Risk: Timely launch and clinical adoption of key pipeline assets (IVL, Ultra, ICE, hypertension, Penumbra) will be decisive for 2028+ acceleration.
- Competitive and Market Dynamics: Watchman faces both clinical evidence headwinds and looming new competition, while EP is exposed to rapid PFA adoption and share shifts.
- Capital Allocation Flexibility: Management’s disciplined approach to M&A and share repurchases provides optionality but heightens execution risk if integration or launches falter.
Risks
Material risks include sustained declines in Watchman referrals due to evolving clinical evidence, further competitive share loss in U.S. EP, and potential delays or underperformance in pipeline launches. Margin pressure from product mix and restructuring costs could persist longer if base business growth falters or if new launches fail to scale. Regulatory changes, reimbursement cuts, and new entrants in key categories (especially Watchman) add uncertainty to the revenue base and growth outlook.
Forward Outlook
For Q3 2026, Boston Scientific guided to:
- Organic revenue growth of 3% to 5%
- Adjusted EPS of $0.80 to $0.82
For full-year 2026, management maintained guidance of:
- Organic revenue growth of 5% to 6%
- Adjusted EPS of $3.28 to $3.32 (7% to 8% growth)
Management highlighted several factors that shape the outlook:
- Flat to declining growth in Watchman and EP through 2027, with recovery expected only after major launches in 2028.
- Restructuring savings and pipeline launches are expected to drive a return to double-digit EPS growth post-2027.
Takeaways
- Growth Model Under Pressure: The abrupt deceleration in Watchman and EP has forced a reset in both guidance and strategic focus, with the diversified core portfolio now responsible for maintaining growth momentum.
- Cost Action and Pipeline Critical: Successful execution on $500 million in cost savings and timely delivery of high-impact pipeline launches are essential for restoring margin and growth in 2028 and beyond.
- Investor Watchpoints: Monitor the stabilization of Watchman and EP trends, progress on restructuring, and clinical/commercial milestones for new platforms as indicators for upside or further downside risk.
Conclusion
Boston Scientific enters a period of transition, absorbing near-term headwinds in two former growth engines while betting on a diversified portfolio and a robust pipeline to drive the next growth cycle. The company’s ability to deliver on cost savings and execute multiple high-impact launches will dictate its return to peer-leading growth and margin expansion in 2028 and beyond.
Industry Read-Through
BSX’s abrupt Watchman and EP slowdowns signal that even market leaders are vulnerable to rapid shifts in clinical evidence and competitive dynamics, especially in procedure-driven medtech segments. The company’s pivot to cost discipline and pipeline-driven growth is likely to be echoed across the sector as peers face similar pressures. The success or failure of Boston’s restructuring and launch cadence will serve as a bellwether for how diversified medtechs can navigate portfolio transitions, margin pressure, and the challenge of offsetting mature product headwinds with new platforms. Investors in the broader medical device industry should watch for similar guidance resets and restructuring waves as the landscape evolves.